Advertisement
Home Tags Deep Vein Thrombosis

Tag: Deep Vein Thrombosis

Initial standalone D-dimer testing followed by whole-leg compression ultrasonography in patients with positive D-dimer can safely rule out deep vein thrombosis

Negative D-Dimer Can Safely Rule Out DVT as Standalone Test

Standalone D-dimer testing followed by whole-leg compression US in positive patients rules out DVT
Following nonmajor orthopedic surgery of the lower limb

Rivaroxaban Prevents VTE After Lower-Limb Surgery

Rivaroxaban superior to enoxaparin for preventing major VTE after nonmajor orthopedic surgery
Insulin and other biologic drugs

FDA: Insulin Among Drugs Transitioned to Biological Products

New regulatory pathway for biologic drugs allows for approval of biosimilars, interchangeable versions
For patients with deep vein thrombosis

Metabolic Syndrome May Up Risk for VTE Recurrence After DVT

Significantly higher odds seen for all four components of MetS, with largest risk increase for hyperlipidemia
Real-world evidence shows that rivaroxaban reduces the risk for recurrent venous thromboembolism in morbidly obese patients

Rivaroxaban Cuts Recurrent Blood Clots in Obese Patients

Patients on rivaroxaban also have lower health care resource utilization than those on warfarin
Fragmin (dalteparin sodium) injection has been granted the first approval for subcutaneous use in preventing recurrence of symptomatic venous thromboembolism in children aged 1 month or older

First Anticoagulant Approved for Preventing VTE Recurrence in Children

Boxed warning lists risk for epidural, spinal hematomas with neuraxial anesthesia, spinal puncture
The likelihood of residual vein obstruction is reduced with immediate compression after diagnosis of deep vein thrombosis

Residual Vein Obstruction Down With Compression After DVT

RVO less likely for those receiving compression within 24 hours of diagnosis of deep vein thrombosis
Compared to vascular experts

PCPs Perform Ultrasound for DVT Similarly to Vascular Experts

However, further training could improve general practitioners' sensitivity
Restarting anticoagulation therapy may be cost-effective for patients with a predicted one-year venous thromboembolism risk of 17.5 percent or higher

Restarting Anticoagulation in Certain VTE Cases Cost-Effective

Treating patients with predicted VTE risk of 17.5 percent or more may be cost-effective
In the elderly

Subclinical Hypothyroidism May Not Up VTE Recurrence Risk

Also, subclinical hyperthyroidism may be associated with lower risk of recurrent VTE in the elderly